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ABSTRACT
Introduction: Adapalene 0.1%/benzoyl
peroxide 2.5% (0.1% A/BPO) and adapalene
0.3%/BPO 2.5% (0.3% A/BPO) gels are
fixed-combination options for the topical
treatment of acne. However, the active
compounds of these combinations are also
available as monads, to be used in association
or as monotherapy. These two in vitro studies
determined the effect of different treatment
regimens on the percutaneous absorption of
adapalene (0.1% and 0.3%) gels and BPO 2.5%
gel in ex vivo human skin.
Methods: In vitro percutaneous absorption
studies were conducted using full-thickness
human skin from six donors. Treatment
regimens included the application of 0.1%
A/BPO, 0.3% A/BPO, or four free-combination
regimens of the monads. Skin samples were
incubated for 24 h. Concentrations of
adapalene and BPO equivalent (BPO-eq) (i.e.
benzoic acid after chemical transformation of
BPO) were measured using high-performance
liquid chromatography. Comparison of
regimens was performed using a
bioequivalence criterion (estimated ratio
bewteen 0.8 and 1.25).
Results: The fixed combination 0.3% A/BPO
regimen demonstrated more than three times
higher absorption of adapalene versus the
fixed-combination 0.1% A/BPO. Based on the
bioequivalence acceptance criterion, all four
free-combination regimens were different from
0.1% A/BPO and 0.3% A/BPO, with higher
adapalene release delivered by the fixed
combinations versus the free combinations. For
BPO-eq, the results showed that the
free-combination regimens where adapalene
0.1% was applied first were different from 0.1%
A/BPO, with lower BPO-eq release delivered by
these regimens compared to the fixed
combination. The regimen adapalene 0.3% for
10 h followedbyBPO2.5%delivered lowerBPO-eq
release compared to the fixed combination.
Conclusion: The fixed-combination A/BPO gels
provide optimal percutaneous absorption of the
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active compounds compared to free
combinations of adapalene 0.1%, adapalene
0.3%, and BPO 2.5%. The higher
concentration of adapalene in the 0.3% A/BPO
gel and the resulting higher absorption may
explain higher clinical efficacy.
Keywords: Adapalene/benzoyl peroxide gel;
Fixed combination; In vitro; Optimal
percutaneous absorption
INTRODUCTION
Acne is a chronic disease which results in
significant psychological burden and reduced
quality of life for patients [1]. The disease has
been ranked as the eighth most prevalent
disease worldwide [2]. Prompt and effective
treatment is crucial for the prevention of acne
sequelae [3]. The current armamentarium for
the topical treatment of acne includes an array
of agents which can be used in combination [4].
A combination recommended by international
guidelines for the topical treatment of acne
involves the use of a retinoid, such as
adapalene, with benzoyl peroxide (BPO) [4–6].
Adapalene possesses comedolytic,
anticomedogenic, and anti-inflammatory
properties [7–11]. The efficacy and safety of
adapalene 0.1% gel has been demonstrated in
clinical studies [10–12]. Further studies have
reported that a higher concentration of the
formulation (adapalene 0.3% gel) shows superior
efficacyanda similar tolerabilityprofile compared
to adapalene 0.1% gel and vehicle [13, 14].
Clinical data have also demonstrated that
adapalene 0.3% gel was safe and effective in the
long-term (12 months) treatment of patientswith
acne [15]. BPO is the antimicrobial agentof choice
due to its bactericidal properties against
Propionibacterium acnes (P. acnes), and absence of
antibiotic resistance [16–18]. Formulations of
both active compounds are available as monads,
to be used in association or as monotherapy for
the treatment of acne.
Adapalene 0.1%/BPO 2.5% gel (Epiduo;
Galderma, Lausanne, Switzerland) (0.1%
A/BPO) is an antibiotic-free, fixed-dose
combination of adapalene and BPO, which is
efficacious in mild-to-moderate acne [16–19].
Data from randomized clinical studies
demonstrated that 0.1% A/BPO provided
synergistic and significantly greater efficacy
than its monads in the treatment of acne,
with an acceptable safety profile [17–21].
Recent clinical evidence, demonstrated the
significantly greater efficacy of higher
concentration adapalene 0.3%/BPO 2.5%
fixed-dose topical gel (Epiduo Forte;
Galderma) (0.3% A/BPO) compared to vehicle
as well as a good safety profile in patients with
moderate-to-severe acne, increasing treatment
options [22]. Although it has been
demonstrated that the fixed combination can
provide superior success in the reduction of
acne lesions and an improvement in the clinical
condition of patients compared to that of its
monads [16–21], there are no data on the drug
bioavailability and bioequivalence of these
agents. In vitro percutaneous absorption
studies could be used for the comparison of
these treatment regimens [23, 24].
The objective of these two studies was to
determine the effect of different treatment
regimens on the percutaneous absorption of
adapalene (0.1% and 0.3%) gel and BPO 2.5%
gel in ex vivo human skin.
METHODS
In vitro percutaneous absorption studies were
conducted using full-thickness human skin
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from three donors (per study), mounted on
polycarbonate membrane inserts of 6-well
culture plates. Skin samples of about 2 9 2 cm
were cut out from the isolated skin after careful
removal of subcutaneous fat. Skin samples were
then carefully transferred into six-well plates on
a Transwell insert which allows contact of the
receptor fluid to the dermal side of the skin
sample, while the stratum corneum remains
exposed to the air. Glass cylinders of 1 cm2
surface were glued to the epidermal side of the
skin sample using cyanoacrylate-based glue.
This keeps the skin flat and in constant
contact with the receptor liquid and prevents
bending.
A dose of 10 mg/cm2 of each formulation
was applied on the skin surface (application area
of 1 cm2) and 2 mL of phosphate buffer saline
were added in the receptor compartment. A
dose of 10 mg/cm2 was chosen taking into
account the clinical use conditions (1–5 mg/
cm2) and the sensitivity of analytical methods.
The 0.1% A/BPO study included the
following treatment regimens:
• 0.1% A/BPO gel
• BPO 2.5% gel for 10 min followed by
adapalene 0.1% gel.
• Adapalene 0.1% gel for 10 min followed by
BPO 2.5% gel.
• BPO 2.5% gel for 10 h followed by adapalene
0.1% gel.
• Adapalene 0.1% gel for 10 h followed by BPO
2.5% gel.
The 0.3% A/BPO study included the
following treatment regimens:
• 0.3% A/BPO gel
• BPO 2.5% gel for 10 min followed by
adapalene 0.3% gel.
• Adapalene 0.3% gel for 10 min followed by
BPO 2.5% gel.
• BPO 2.5% gel for 10 h followed by adapalene
0.3% gel.
• Adapalene 0.3% gel for 10 h followed by BPO
2.5% gel.
The sequential application of monads
separated by 10 min was chosen in order to
simulate the use of both monads in association
at the same time by the patient. The sequential
application of monads separated by 10 h was
chosen in order to simulate the use of monad as
monotherapy. This interval was chosen to
mimic morning/evening application of each
monad in patient use conditions while
respecting technical and operational
constraints of the ex vivo test.
Skin samples were incubated (37 C and 5%
CO2) for 24 h. Each condition was performed in
triplicate for each of the three donors (i.e.
n = 9). Concentrations of adapalene and BPO
equivalent (BPO-eq) (i.e. benzoic acid after
chemical transformation of BPO) were
measured using high-performance liquid
chromatography.
Comparison between the different treatment
regimens was performed using the geometric
mean ratio of test/reference treatment approach
a (bioequivalence criterion estimated ratio of
geometric means between 0.8 and 1.25).
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by




Three full-thickness skin samples from three
female donors, aged 56–79 years, were used in
the study. The skin sample thickness ranged
between 1.7 and 2.2 mm.
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Adapalene Release
Figure 1 illustrates the total penetrated
adapalene for 0.1% A/BPO. Based on the
bioequivalence acceptance criterion, the
results showed that all free-combination
regimens were different from 0.1% A/BPO gel,
with geometric mean ratios outside the
acceptance interval of 80–120% (Fig. 2). The
0.1% A/BPO gel showed higher adapalene
release compared to all monad formulations.
BPO-eq Release
Figure 3 illustrates the total penetratedBPO-eq for
0.1% A/BPO. According to the bioequivalence
acceptance criterion, the free-combination
regimens with application of adapalene 0.1% gel
prior to BPO 2.5% gel were different from A/BPO
gel treatment (Fig. 4). The0.1%A/BPOgel showed




Three full-thickness skin samples from 2 male
and 1 female donors, aged 31–55 years, were
used in the study. The skin sample thickness
was between 1.6 and 3.2 mm.
Fig. 1 Adapalene: total penetrated into skin (lg/cm2)
(mean and standard error of the mean)
Fig. 2 Adapalene: comparison between treatment regimens (geometric mean ratio, %). Asterisk outside the acceptance
interval of 80–125% (\80%)
Fig. 3 BPO-eq: total penetrated into skin (lg/cm2) (mean
and standard error of the mean)
126 Dermatol Ther (Heidelb) (2017) 7:123–131
Adapalene Release
Figure 1 illustrates the total penetrated adapalene
for 0.3%A/BPO. Skin penetration of adapalene in
0.3%A/BPOgel wasmore than three times higher
than in 0.1%A/BPO gel. Thismay be explained in
part by the sensitivity of the limits of analytical
method thatmyunderestimate theconcentration
of adapalene in 0.1% A/BPO gel.
Based on the bioequivalence acceptance
criterion, the results showed that all
free-combination regimens were different from
0.3% A/BPO (Fig. 5). The fixed-combination
0.3% A/BPO gel showed higher adapalene
release compared to all free combinations of
monad formulations.
BPO-eq Release
Figure 3 illustrates the total penetrated BPO-eq
for 0.3% A/BPO. The regimen adapalene 0.3%
for 10 h followed by BPO 2.5% showed lower
BPO-eq release when compared to that observed
for 0.3% A/BPO (Fig. 6).
Fig. 4 BPO-eq: comparison between treatment regimens (geometric mean ratio, %). Asterisk outside the acceptance interval
of 80–125% (\80%)
Fig. 5 Adapalene: comparison between treatment regimens (geometric mean ratio, %). Asterisk outside the acceptance
interval of 80–125% (\80%)
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DISCUSSION
The studies described in this article investigated
the effect of different treatment regimens on
the percutaneous absorption of adapalene
(0.1% and 0.3%) gel and BPO 2.5% gel in
ex vivo human skin.
Comparison between the different treatment
regimens was performed using the geometric
mean ratio of test/reference treatment
approach, since quantities recovered in the
skin in this kind of experiment generally show
a distribution skewed to the right and
logarithmic transformation of the data
normalizes the distribution (making it
symmetrical). Moreover, a geometric mean of
different ratios has the advantage of being the
same as the ratio of different geometric means, a
property that arithmetic means do not have.
Comparison of the two fixed combinations
demonstrated more than three times higher
absorption of adapalene in the 0.3% A/BPO
regimen versus 0.1% A/BPO. In previous clinical
studies on adapalene, it was demonstrated that
0.3% A/BPO gel resulted in higher efficacy
compared to 0.1% A/BPO in the treatment of
severe inflammatory acne [22, 25]. The higher
concentration of adapalene in the 0.3% A/BPO
gel and the resulting higher absorption may
explain the higher clinical efficacy. Moreover,
the higher concentration of adapalene did not
lead to lower safety since both 0.3% A/BPO and
0.1% A/BPO were safe and well tolerated [25].
The total amount of penetrated adapalene
was higher after the fixed combinations 0.1%
A/BPO and 0.3% A/BPO compared to that of the
free-combination regimens. The geometric
mean ratios were all out of the acceptance
interval of bioequivalence limits (80–125%),
indicating that all four free-combination
regimens were different from 0.1% A/BPO and
0.3% A/BPO, with higher adapalene release
delivered by the fixed combinations versus any
of the other application regimens. The low level
of adapalene in the free-combination regimens
may be due to the creation of a physical barrier
on the stratum corneum by BPO combined with
the slow release of adapalene.
The results of clinical studies indicated that
fixed combination of A/BPO is more
advantageous compared to the free
combinations of its monads in terms of efficacy
and patient satisfaction [17–21]. Our in vitro
results showing higher release of adapalene in
the fixed combination than in its monads may
explain the higher clinical efficacy.
Fig. 6 BPO-eq: comparison between treatment regimens (geometric mean ratio, %). Asterisk outside the acceptance interval
of 80–125% (\80%)
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Comparison of the two fixed combinations
did not reveal differences in the absorption of
BPO-eq between 0.1% A/BPO and 0.3% A/BPO.
The total amount of penetrated BPO-eq was
not modified in regimens where BPO 2.5% was
applied first nor for adapalene 0.3% for 10 min
followed by the BPO 2.5% regimen. However,
low BPO-eq levels were recovered when
adapalene 0.1% was applied first and for
adapalene 0.3% followed 10 h later by BPO
2.5%. In these regimens, the geometric mean
ratio was out of the acceptance interval limits
with lower BPO-eq release delivered by these
regimens versus the fixed combinaison
regimens. This could be explained by the
creation of a physical barrier on the stratum
corneum by adapalene preventing the
absorption of BPO.
A limitation of these in vitro studies was the
single application of the treatment regimens on
the skin samples. Moreover, such studies cannot
follow the bioequivalence rule of 80–125% by
using 90% confidence intervals (the entire
interval having to be within these limits), due
to the small sample sizes. It is not possible to
conclude equivalence because of variability in
those studies, even if there is strict equality.
Instead, these studies used the point estimate to
be within 80–125% in order to conclude no
difference. However, we found this to be a
better rule than testing for differences by
statistical tests.
Overall, the results of these in vitro studies
indicated that fixed combination 0.3% A/BPO is
better than 0.1% A/BPO gel, and both
fixed-combination gels showed higher release
of adapalene than its monads, and higher BPO
release (according to treatment conditions)
than its monad. The high adapalene
penetration and concentration in the skin may
explain the higher efficacy observed in the
clinic with the fixed combination 0.3% A/BPO.
CONCLUSION
In conclusion, these in vitro studies
demonstrate that fixed-combination A/BPO
gels provide optimal percutaneous absorption
of the active compounds compared to
free-combination regimens of monad
formulations of adapalene 0.1%, adapalene
0.3%, and BPO 2.5%. The higher
concentration of adapalene in the 0.3% A/BPO
gel and the resulting higher absorption may
explain the higher efficacy in the clinic.
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